Metformin (N,N-dimethylbiguanide), a potent anti-diabetic molecule also used in cancer treatment for its anti-tumorigenic properties (104, 105), sensitizes endometrial cancer to progestin by targeting Tet methylcytosine dioxygenase 1 (TET1), which downregulates Glo1 expression (106). Here, TET1 is linked to endometrial cancer.